BioVie (BIVI) News
NASDAQ: BIVIHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
BIVI news summary
We found 7 recent headlines mentioning BioVie (BIVI): 1 in the past week and 6 in the past 30 days, most often from GlobeNewswire, Nasdaq, Business Insider. BIVI is making an outsized move today, down 12.07% at $0.80, which often coincides with company-specific news. Check the latest headlines below for the likely catalyst. The most recent story, "BioVie Presents New Biomarker Data Highlighting Biomarker-Defined Endotypes and Neuropeptide Y Response to Bezisterim at the 4th Long COVID International Conference 2026", was published by GlobeNewswire on Nov 16, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest BioVie headlines
- BioVie Presents New Biomarker Data Highlighting Biomarker-Defined Endotypes and Neuropeptide Y Response to Bezisterim at the 4th Long COVID International Conference 2026New findings from the Phase 2 ADDRESS-LC trial identify two distinct biomarker-defined Long COVID endotypes 1 associated with different patient responses to bezisterim treatment.GlobeNewswire
- BioVie Presents New Biomarker Data from the ADDRESS-LC Trial of Bezisterim in Long COVID at the NIH RECOVER-TLC Third Annual WorkshopNew findings from the Phase 2 ADDRESS-LC trial suggest two distinct biomarker-defined Long COVID endotypes 1 associated with different patient responses to bezisterim treatment.GlobeNewswire
- Fusion Power, Global Capital, Branded Streaming and Neurology Breakthroughs: New to The Street Show #779 Premieres Tonight on Bloomberg Television<i>American Fusion (OTCQB:AMFN), FreeCast (NASDAQ:CAST), Stewards Investment Capital and BioVie (NASDAQ:BIVI) Headline a Four-Region Broadcast Across the U.S., Latin America, MENA and Southeast…Business InsiderCAST, BIVI
- BioVie Inc. Announces Pricing of $4.74 Million Registered Direct Offering and Concurrent Private PlacementOn November 3, 2026, BioVie Inc. entered into a securities purchase agreement with an institutional investor to issue and sell securities in a registered direct offering and a concurrent private…Nasdaq
- BioVie Announces Pricing of $4.74 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq RulesCARSON CITY, Nev., Nov. 04, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (" BioVie " or the " Company "), a clinical-stage company developing innovative drug therapies for neurological and…GlobeNewswire
- BioVie Selected for Late-Breaking Oral Presentation of Bezisterim Long COVID Data at the 4th Long COVID International Conference 2026CARSON CITY, Nev., Nov. 02, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and…GlobeNewswire
- BioVie's Bezisterim Shows Positive Signals In Long COVID Patients With Greater Symptom Burden(RTTNews) - BioVie Inc. (BIVI), a clinical-stage biopharmaceutical company developing therapies for neurological disorders, announced that it presented Phase 2 data on investigational bezisterim…NasdaqBIVI, BRK.B